Clinical Trials Directory

Trials / Completed

CompletedNCT02997111

PFA-100 Responsive to Effect of Energy Drinks on Platelet Function

Is the PFA-100 Responsive to the Effect of Energy Drinks on Platelet Function Changes?

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
13 (actual)
Sponsor
St. Louis University · Academic / Other
Sex
All
Age
18 Years – 35 Years
Healthy volunteers
Accepted

Summary

This study evaluates the responsiveness of the Platelet Function Analyzer (PFA-100) to the effect of energy drinks on platelet function. Participants' will have blood drawn prior to and 60 minutes after ingesting 250ml of a commercially available sugar-free energy drink.

Detailed description

Two previous studies have demonstrated increased platelet aggregation 60 minutes after drinking a commercially available sugar-free energy drink. These studies utilized traditional platelet function studies, such as light transmission aggregometry (LTA), where platelet function is examined while adding varying concentrations of a panel of agonist to platelets. These studies are technically difficult, time intensive studies requiring specialized laboratories. They are relatively non-physiologic and do not mimic platelet response to vessel wall damage. Other tests better represent the reactions to vessel wall damage, including the PFA-100, which measures platelet aggregation and adhesion under conditions of high shear. Overall, PFA-100 is less expensive, requires less technical skill, and is less time consuming than LTA. It has been utilized in bleeding disorders and is demonstrating promise as a marker of thrombophilia. PFA-100 has demonstrated sensitivity to drug and dietary effects. It has also shown differences in closure time between sedentary and athletic individuals PFA-100 has not been used to investigate the effect of energy drinks.

Conditions

Interventions

TypeNameDescription
DEVICEPFA-100The PFA-100 will be used to assess platelet function before and after energy drink consumption.

Timeline

Start date
2017-02-14
Primary completion
2017-06-09
Completion
2017-06-20
First posted
2016-12-19
Last updated
2017-06-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02997111. Inclusion in this directory is not an endorsement.